Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.

Kakuda TN, McClure MW, Westland C, Vuong J, Homery MC, Poizat G, Viguerie L, Denot C, Patat A, Zhang Q, Hui J, Apelian D, Smith DB, Chanda SM, Fry J.

Pharmacol Res Perspect. 2018 Apr 30;6(3):e00395. doi: 10.1002/prp2.395. eCollection 2018 Jun.

2.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.

Cohn A, Morse MA, O'Neil B, Whiting S, Coeshott C, Ferraro J, Bellgrau D, Apelian D, Rodell TC.

J Immunother. 2018 Apr;41(3):141-150. doi: 10.1097/CJI.0000000000000219.

3.

Copper Impurity Effects on LiNi(1/3)Mn(1/3)Co(1/3)O2 Cathode Material.

Sa Q, Heelan JA, Lu Y, Apelian D, Wang Y.

ACS Appl Mater Interfaces. 2015 Sep 23;7(37):20585-90. doi: 10.1021/acsami.5b04426. Epub 2015 Sep 9.

PMID:
26325672
4.

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, Kottilil S, Bellgrau D, Rodell T, Apelian D.

PLoS One. 2014 Jul 22;9(7):e101904. doi: 10.1371/journal.pone.0101904. eCollection 2014.

5.

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study.

Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR, Shen G, Subramanian GM, McHutchison JG.

Vaccine. 2014 Sep 3;32(39):4925-31. doi: 10.1016/j.vaccine.2014.07.027. Epub 2014 Jul 18.

6.

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, Rusch V, Mattson A, Coeshott C, Park B, Apelian DM, Kris MG, Azzoli CG.

Clin Lung Cancer. 2014 Nov;15(6):405-10. doi: 10.1016/j.cllc.2014.06.002. Epub 2014 Jun 21.

PMID:
25044103
7.

Value analysis of neodymium content in shredder feed: toward enabling the feasibility of rare earth magnet recycling.

Bandara HM, Darcy JW, Apelian D, Emmert MH.

Environ Sci Technol. 2014 Jun 17;48(12):6553-60. doi: 10.1021/es405104k. Epub 2014 Jun 5.

PMID:
24934194
8.

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.

Cancer Immunol Immunother. 2014 Mar;63(3):225-34. doi: 10.1007/s00262-013-1505-8. Epub 2013 Dec 7.

9.

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.

10.

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW.

Clin Cancer Res. 2013 Nov 15;19(22):6205-18. doi: 10.1158/1078-0432.CCR-13-1026. Epub 2013 Sep 18.

11.

Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

Cereda V, Vergati M, Huen NY, di Bari MG, Jochems C, Intrivici C, Gulley JL, Apelian D, Schlom J, Tsang KY.

Vaccine. 2011 Jul 12;29(31):4992-9. doi: 10.1016/j.vaccine.2011.04.101. Epub 2011 May 11.

12.

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.

Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW.

Cancer Immunol Immunother. 2011 Sep;60(9):1227-42. doi: 10.1007/s00262-011-1020-8. Epub 2011 May 5.

13.

Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.

Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J.

Vaccine. 2010 Aug 23;28(37):6028-35. doi: 10.1016/j.vaccine.2010.06.085. Epub 2010 Jul 7.

14.

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC.

Vaccine. 2007 Feb 9;25(8):1452-63. Epub 2006 Nov 10.

PMID:
17098335
15.

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1001-10.

16.

A new putative sigma factor of Myxococcus xanthus.

Apelian D, Inouye S.

J Bacteriol. 1993 Jun;175(11):3335-42.

17.

Supplemental Content

Loading ...
Support Center